Erkang Pharmaceuticals: Controlling shareholder Shuai Fangwen plans to reduce his holdings by no more than 2.04%.

Erkang Pharmaceutical announced that its controlling shareholder Shuai Fangwen holds 854 million shares, accounting for 41.38% of the total shares. He plans to reduce his holdings by no more than 42 million shares, or 2.04%, from April 23, 2026 to July 22, 2026, through centralized bidding or block trading. Within any consecutive ninety days, the reduction through bidding will not exceed 1% and through block trading will not exceed 2%. The reduction price will not be lower than the initial public offering price, and the reason for the reduction is for personal capital needs.